Cover Image
市場調查報告書

腦下垂體ACTH過度分泌 (庫欣氏症候群) :開發中產品分析

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 253635
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
腦下垂體ACTH過度分泌 (庫欣氏症候群) :開發中產品分析 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 56 Pages
簡介

庫欣氏症候群是指腦下垂體過度分泌腎上腺皮質刺激荷爾蒙 (ACTH) 的狀態。症狀有粉刺、皮膚感染、腰痛、精神的變化、觀察可見行為的變化,頭痛等。治療方法包含外科手術和放射線治療。

本報告提供腦下垂體ACTH過度分泌 (庫欣氏症候群) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腦下垂體ACTH過度分泌 (庫欣氏症候群) 概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cortendo AB
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ipsen S.A.
  • Isis Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALD-1613
  • AT-814
  • ATR-101
  • BIM-23A758
  • COR-005
  • CORT-125134
  • ISIS-GCCRRx
  • ketoconazole
  • mifepristone
  • MPP-482
  • osilodrostat
  • pasireotide LAR
  • Peptides to Antagonize ACTH Receptor for Cushing's Syndrome
  • seliciclib
  • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease
  • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
  • Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
  • Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9460IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
    • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
    • Amryt Pharma plc
    • Crinetics Pharmaceuticals Inc
    • Cyclacel Pharmaceuticals Inc
    • Ipsen SA
    • Millendo Therapeutics Inc
    • Novartis AG
    • Pfizer Inc
    • Strongbridge Biopharma plc
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing's syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIM-23B065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levoketoconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPP-482 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • osilodrostat phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seliciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Cushing Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Melanocortin Receptor 2 for ACTH-dependent Cushing's syndrome and Congenital Adrenal Hyperplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veldoreotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
      • Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases
      • Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
      • Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014
      • Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014
      • Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
      • Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
      • Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial
      • Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome
      • Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing's Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Millendo Therapeutics Inc, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Pfizer Inc, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H1 2017
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top